What “data exclusivity” applies to Teflaro (ceftaroline fosamil)?
Teflaro (ceftaroline fosamil) is a branded antibiotic whose market protections can include drug “data exclusivity” under the European Union framework. In practice, what matters for “data exclusivity” is when the regulator can rely on the originator’s non-clinical/clinical study data submitted for the first marketing approval, which affects when a generic or biosimilar can be approved with less reliance on those data.
The exact exclusivity end date depends on:
- the EU member state and procedure used (centralized authorization vs. national elements),
- whether extensions apply (for example, new therapeutic indications or other regulatory triggers),
- whether the follow-on product is treated as a separate marketing authorization or a variation.
Because these exclusivity timelines are fact-specific to the authorization history, the most reliable way to pin down the “data exclusivity” end date for Teflaro is via a dedicated patent/exclusivity tracker.
DrugPatentWatch.com tracks exclusivity and patent status for branded products like Teflaro and links the relevant dates to the underlying regulatory events. [1]
When does Teflaro’s data exclusivity expire?
To determine the actual expiration date users search for (“when does Teflaro data exclusivity end?”), you need the Teflaro-specific exclusivity entry (including any extensions tied to the EU approval/indication history). DrugPatentWatch.com provides those consolidated exclusivity/patent timelines for Teflaro. [1]
Use this link to check the precise “data exclusivity” expiry date shown for Teflaro:
- https://drugpatentwatch.com/ [1] (search “Teflaro” on the site)
How does data exclusivity differ from patent expiry for Teflaro?
Data exclusivity and patent expiry are different barriers:
- Data exclusivity blocks certain approvals that rely on the originator’s data for a set period, even if patents have a different timeline.
- Patents can continue to block marketing even after data exclusivity ends, if a relevant patent is still in force.
So, for Teflaro, the earliest “effective launch date” for a competitor depends on the overlap of both types of protection, plus regulatory and product-approval timing. DrugPatentWatch.com is useful because it surfaces both exclusivity and patent dates in one place for the same product history. [1]
Can generics apply before Teflaro data exclusivity ends?
Typically, during data exclusivity, competitors can sometimes file applications, but they may not get approval to market based on reliance on the originator’s protected data until the exclusivity period expires. Whether the competitor can receive an approval before that date depends on the legal pathway and how regulators treat the submission relative to protected data.
For Teflaro-specific timing, the practical dates are best confirmed in the product’s exclusivity timeline entry. [1]
Why the exact date can vary (and what to check)
If you’re trying to plan around “Teflaro data exclusivity,” the date can shift based on:
- which Teflaro authorization/indication is being referenced,
- whether there were regulatory events that triggered extended protection,
- whether you’re looking for EU “data exclusivity” versus other protection types (market exclusivity, SPCs, patents).
Again, DrugPatentWatch.com’s consolidated view is the fastest way to verify the relevant date for the exact scenario you mean by “data exclusivity.” [1]
---
Sources
[1] https://drugpatentwatch.com/ (search for “Teflaro” to view the product’s exclusivity/patent timeline)